Can You Take Wellbutrin and Adderall Together?
Yes, you can safely take Wellbutrin (bupropion) and Adderall (mixed amphetamine salts) together in most adults, though this combination requires careful monitoring for seizure risk and cardiovascular effects.
Key Safety Considerations
The primary concern when combining these medications is seizure risk. Bupropion lowers the seizure threshold, and while there are no published case reports of adverse interactions between bupropion and stimulants 1, clinicians must proceed with appropriate caution.
Absolute Contraindications to This Combination:
- Seizure disorders or history of seizures 2
- Brain metastases or stroke (due to increased seizure risk) 3
- Eating disorders (anorexia/bulimia - increases seizure risk with bupropion)
- Abrupt discontinuation of alcohol or benzodiazepines (lowers seizure threshold further)
Relative Contraindications Requiring Extra Caution:
- Uncontrolled hypertension - both medications can elevate blood pressure 2
- Cardiovascular disease - stimulants increase heart rate and blood pressure
- Concurrent use of other medications that lower seizure threshold 4
Evidence Supporting Safe Co-Administration
The available evidence, while limited for this specific combination, is reassuring:
Direct evidence: A 2002 guideline on stimulant use explicitly states: "There are no studies of the combination of bupropion and stimulants in the treatment of ADHD or other psychiatric conditions. The PDR does not warn against interactions between bupropion and stimulants, and we could locate no case reports of side effects when these agents were combined" 1.
Indirect evidence from methamphetamine studies: Research examining bupropion with intravenous methamphetamine (a more potent stimulant than Adderall) found the combination was well-tolerated with no additive cardiovascular effects. In fact, bupropion actually reduced methamphetamine-associated increases in heart rate 5. This suggests the combination may be safer than theoretically expected.
Clinical practice: Recent meta-analyses and trials continue to study bupropion with amphetamine-type stimulants for substance use disorders, with acceptable safety profiles 6, 7.
Monitoring Requirements
When prescribing this combination:
Baseline Assessment:
- Personal and family history of seizures
- Cardiovascular history and current blood pressure
- Current medications (especially other seizure threshold-lowering drugs)
- History of eating disorders
- Substance use history
Ongoing Monitoring:
- Blood pressure and heart rate should be checked periodically, especially in the first 12 weeks 2
- Monitor for signs of overstimulation: excessive anxiety, agitation, insomnia, tremor
- Watch for any seizure activity or warning signs
- Assess for mood changes, including activation of mania/hypomania 4
Dosing Considerations
- Start bupropion at lower doses and titrate gradually to minimize seizure risk
- Maximum bupropion dose should not exceed 450 mg/day (seizure risk increases at higher doses) 4
- Avoid taking the second daily dose of bupropion late in the day to minimize insomnia 2
- Standard Adderall dosing can be used, but consider starting conservatively
Clinical Advantages of This Combination
This combination may be particularly beneficial for patients with:
- ADHD with comorbid depression - addresses both conditions 8, 9
- ADHD with smoking cessation needs - bupropion aids smoking cessation 2
- Patients concerned about stimulant appetite suppression - bupropion may help with weight management 2
Common Pitfalls to Avoid
- Don't combine if seizure risk factors are present - this is the most critical safety concern
- Don't ignore cardiovascular monitoring - both drugs affect blood pressure and heart rate
- Don't use with MAOIs - bupropion should not be used within 14 days of MAOI discontinuation 2, 4
- Don't exceed maximum bupropion doses - seizure risk is dose-dependent
Bottom Line
The combination of Wellbutrin and Adderall can be used safely in appropriately selected patients without seizure risk factors or significant cardiovascular disease. The lack of reported adverse interactions in clinical practice and research, combined with evidence showing no additive cardiovascular effects, supports the safety of this combination when proper monitoring is implemented 1, 5.